GynecologyGynecology2079-56962079-5831Consilium Medicum28211Research ArticlePossibilities of early treatment and prophylaxis of papillomavirus infectionPrilepskayaV NVPrilepskaya@mail.ruNovikovaE Ptaukita.matsuda@gmail.com15022013151949709042020Copyright © 2013, Consilium Medicum2013Isoprinosine is included to European standards of patient management with papillomavirus infection. The double antiviral drug action consists in inhibition of enzyme dihydropteroate synthetase which is involved in viral replication and suppression of viral protein production due to changes of stereochemical structure of the cell ribosome. The article presents aspects of prophylaxis of cervical cancer and modern approaches of treatment methods for papillomavirus infection.HPVisoprinosineprophylaxis of cervical cancerвирус папилломы человекаИзопринозинпрофилактика рака шейки матки[Стратегический документ «Подготовка к внедрению вакцины против ВПЧ в Европейском регионе». ВОЗ, 2008 г.][Centers for Disease Control and Prevention. STD trends in the United States: 2010 national data for gonorrhea, chlamydia, and syphilis. Available at http://www.cdc.gov/std/stats10/trends.htm. Accessed October 24, 2012.][Clifford G.M, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366 (9490): 991–8 [Medline].][Woodman C.B, Collins S.I, Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11–22.][Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008; 110: S4–S7.][Snijders P.J, Steenbergen R.D, Heideman D.A, Meijer C.J. HPV - mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152–64.][Einstein H, Schiller J.T, Viscidi R.P et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347–56.][Lepique A.P, Rabachini T, Villa L.L. HPV vaccination: the beginning of the end of cervical cancer? A Review. Mem Inst Oswaldo Cruz 2009; 104: 1–10.][Azar K.K, Tani M, Yasuda H et al. Increased secretion patterns of interleukin-10 and tumor necrosis factor - alpha in cervical squamous intraepithelial lesions. Hum Pathol 2004; 35: 1376–84.][Goldie S.J, Kuhn L, Denny L et al. Policy analysis of cervical cancer screening strategies in low - resource settings: clinical benefits and cost - effectiveness. JAMA 2001; 285: 3107–115.][Petry K.U, Menton S, Menton M et al: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570–7.][Arbyn M, Simoens C, Van O.H et al. Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996–2000). Prev Med 2009; 48: 438–43.][Dehn D, Torkko K.C, Shroyer K.R. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007; 111: 1–14.][Европейская ассоциация по патологии шейки матки и кольпоскопии, 2008.][Шварц Г.Я., Прилепская В.Н., Мынбаев О.А. Изопринозин в лечении папилломавирусной инфекции в гинекологической практике. М.: Промоушн - микс, 2011.][Резолюция круглого стола российских специалистов. Разработка эффективных подходов к ведению пациентов с «минимальным» повреждением эпителия шейки матки и ВПЧ - инфекцией «XI-й Международный симпозиум по проблемам патологии нижнего отдела генитального тракта. Папилломавирусная инфекция: глобальная битва». Рим, 21 апреля 2012 г.]